/DISREGARD RELEASE: NeuroGen/
- Written by PR Newswire
We are advised by NeuroGen that journalists and other readers should disregard the news release, China's First CGRP Targeted Therapy to Enter the NRDL: NeuroGen Officially Launches Ajovy® (fremanezumab), Benefiting the First Cohort of Migraine Patients, issued 18-Nov-2026 over PR Newswire. The release has been withdrawn following a change to the issuer's distribution arrangements.
Read more https://en.prnasia.com/story/archive/5101067_AE01067_0














